The oral cavity is frequently affected in chronic graft-versus-host disease (cGVHD), with variable clinical presentations. The literature on the effective management of patients suffering from oral cGVHD is limited.
The objective of this study was to assess the clinical approaches used in the diagnosis and treatment of cGVHD in a group of health-care providers specialized in the oral care of oncology patients. The secondary objective was to assess the level of implementation of the National Institutes of Health (NIH) guidelines for cGVHD patients.
One hundred twenty questionnaires were sent to the members of the Oral Care Study Group (OCSG) of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). The questionnaire included 50 questions about the responder’s demographics, level of exposure to cGVHD patients, diagnostic and evaluation methods in their practice, preferred treatment strategies for mucosal and salivary gland involvement, and preventive measures.
Twelve responders, representing 12 sites, stated that they treat oral cGVHD patients on a regular basis. This fraction of responders was confirmed by another online survey. Eleven out of the 12 providers were dentists. Seventy-five percent of the providers did not use biopsy in order to diagnose oral cGVHD. The NIH scale for the clinical assessment was used sporadically. The first-line topical treatment for oral mucosal cGVHD was predominantly steroids (91.7 %), and the second preferred treatment was tacrolimus (41.7 %). The preferred treatment for hyposalivation was pilocarpine (41.7 %). The recommended frequency of oral cancer screening varied; half of the providers suggest a follow-up every 6 months.
The responses described the common practices for oral cGVHD in several specialized centers across the world. The choice of topical treatments was influenced by the availability of medications in the provider’s country.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Socie G, Ritz J (2014) Current issues in chronic graft-versus-host disease. Blood 124(3):374–384
Blazar BR, Murphy WJ, Abedi M (2012) Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 12(6):443–458
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956
Schubert MM, Correa ME (2008) Oral graft-versus-host disease. Dent Clin North Am 52(1):79–109, viii-ix
Kuten-Shorrer M, Woo SB, Treister NS (2014) Oral graft-versus-host disease. Dent Clin North Am 58(2):351–368
Daikeler T, Mauramo M, Rovo A, Stern M, Halter J, Buser A et al (2013) Sicca symptoms and their impact on quality of life among very long-term survivors after hematopoietic SCT. Bone Marrow Transplant 48(7):988–993
Treister NS, Cook EF Jr, Antin J, Lee SJ, Soiffer R, Woo SB (2008) Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 14(1):110–115
Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW et al (2006) Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report. Biol Blood Marrow Transplant 12(3):252–266
Schubert MM, Sullivan KM (1990) Recognition, incidence, and management of oral graft-versus-host disease. NCI Monogr 9:135–143
Garcia FVMJ, Pascual-Lopez M, Elices M, Dauden E, Garcia-Diez A, Fraga J (2002) Superficial mucoceles and lichenoid graft versus host disease: report of three cases. Acta Derm Venereol 82(6):453–455
Mays JW, Fassil H, Edwards DA, Pavletic SZ, Bassim CW (2013) Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research. Oral Dis 19(4):327–346
Couriel D, Carpenter PA, Cutler C, Bolanos-Meade J, Treister NS, Gea-Banacloche J et al (2006) Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 12(4):375–396
Mawardi H, Elad S, Correa ME, Stevenson K, Woo SB, Almazrooa S et al (2011) Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant 46(6):884–891
Treister N, Duncan C, Cutler C, Lehmann L (2012) How we treat oral chronic graft-versus-host disease. Blood 120(17):3407–3418
Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C et al (2012) Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Bone Marrow Transplant 47(3):337–341
Schubert MM, Williams BE, Lloid ME, Donaldson G, Chapko MK (1992) Clinical assessment scale for the rating of oral mucosal changes associated with bone marrow transplantation. Development of an oral mucositis index. Cancer 69(10):2469–2477
Meier JK, Wolff D, Pavletic S, Greinix H, Gosau M, Bertz H et al (2011) Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD. Clin Oral Investig 15(2):127–139
Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G et al (2012) Organ-specific management and supportive care in chronic graft-versus-host disease. Br J Haematol 158(1):62–78
McCormack HM, Horne DJ, Sheather S (1988) Clinical applications of visual analogue scales: a critical review. Psychol Med 18(4):1007–1019
Elad S, Zeevi I, Finke J, Koldehoff M, Schwerdtfeger R, Wolff D et al (2012) Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide—an open, randomized, multicenter study. Biol Blood Marrow Transplant 18(1):134–140
Park AR, La HO, Cho BS, Kim SJ, Lee BK, Rhie JY et al (2013) Comparison of budesonide and dexamethasone for local treatment of oral chronic graft-versus-host disease. Am J Health Syst Pharm 70(16):1383–1391
Noce CW, Gomes A, Shcaira V, Correa ME, Moreira MC, Silva Junior A et al (2014) Randomized double-blind clinical trial comparing clobetasol and dexamethasone for the topical treatment of symptomatic oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 20(8):1163–1168
Sari I, Altuntas F, Kocyigit I, Sisman Y, Eser B, Unal A et al (2007) The effect of budesonide mouthwash on oral chronic graft versus host disease. Am J Hematol 82(5):349–356
Fortune K, Couriel D (2009) Tacrolimus in hematopoietic stem cell transplantation. Expert Opin Drug Metab Toxicol 5(7):835–841
Mawardi H, Stevenson K, Gokani B, Soiffer R, Treister N (2010) Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant 45(6):1062–1067
Brown RS, Edwards D, Walsh-Chocolaad T, Childs RW (2013) Topical tacrolimus with custom trays in the treatment of severe oral chronic graft-versus-host disease refractory to a potent topical steroid therapy: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 115(4):e26–e30
Eckardt A, Starke O, Stadler M, Reuter C, Hertenstein B (2004) Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: highly effective treatment with topical tacrolimus. Oral Oncol 40(8):811–814
Fricain JC, Sibaud V, Swetyenga N, Tabrizi R, Campana F, Taieb A (2007) Long-term efficacy of topical tacrolimus on oral lesions of chronic graft-versus-host disease. Br J Dermatol 156(3):588–590
Conrotto D, Broccoletti R, Carcieri P, Giaccone L, Arduino PG (2014) Topical tacrolimus and periodontal therapy in the management of a case of oral chronic GVHD characterized by specific gingival localization. Case Rep Dent 2014:127219
Elad S, Or R, Shapira MY, Haviv A, Galili D, Garfunkel AA et al (2003) CO2 laser in oral graft-versus-host disease: a pilot study. Bone Marrow Transplant 32(10):1031–1034
Nozaki-Taguchi N, Shutoh M, Shimoyama N (2008) Potential utility of peripherally applied loperamide in oral chronic graft-versus-host disease related pain. Jpn J Clin Oncol 38(12):857–860
Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J (1997) Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies. Leuk Lymphoma 24(5–6):539–543
Nagler RM, Nagler A (1999) Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study. Bone Marrow Transplant 23(10):1007–1011
Agha-Hosseini F, Mirzaii-Dizgah I, Ghavamzadeh L, Ghavamzadeh A, Tohidast-Acrad Z (2007) Effect of pilocarpine hydrochloride on unstimulated whole saliva flow rate and composition in patients with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 39(7):431–434
Carpenter PA, Schubert MM, Flowers ME (2006) Cevimeline reduced mouth dryness and increased salivary flow in patients with xerostomia complicating chronic graft-versus-host disease. Biol Blood Marrow Transplant 12(7):792–794
Castellarin P, Stevenson K, Biasotto M, Yuan A, Woo SB, Treister NS (2012) Extensive dental caries in patients with oral chronic graft-versus-host disease. Biol Blood Marrow Transplant 18(10):1573–1579
Epstein JB, Gorsky M, Fischer D, Gupta A, Epstein M, Elad S (2007) A survey of the current approaches to diagnosis and management of oral premalignant lesions. J Am Dent Assoc 138(12):1555–1562, quiz 614
Atsuta Y, Suzuki R, Yamashita T, Fukuda T, Miyamura K, Taniguchi S et al (2014) Continuing increased risk of oral/esophageal cancer after allogeneic hematopoietic stem cell transplantation in adults in association with chronic graft-versus-host disease. Ann Oncol 25(2):435–441
Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM et al (2011) Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood 117(1):316–322
Kruse AL, Gratz KW (2009) Oral carcinoma after hematopoietic stem cell transplantation—a new classification based on a literature review over 30 years. Head Neck Oncol 1:29
Elad S, Zadik Y, Zeevi I, Miyazaki A, de Figueiredo MA, Or R (2010) Oral cancer in patients after hematopoietic stem-cell transplantation: long-term follow-up suggests an increased risk for recurrence. Transplantation 90(11):1243–1244
Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB et al (1997) Solid cancers after bone marrow transplantation. N Engl J Med 336(13):897–904
Elad S, Zeevi I, Or R, Resnick IB, Dray L, Shapira MY (2010) Validation of the National Institutes of Health (NIH) scale for oral chronic graft-versus-host disease (cGVHD). Biol Blood Marrow Transplant 16(1):62–69
Treister NS, Stevenson K, Kim H, Woo SB, Soiffer R, Cutler C (2010) Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. Biol Blood Marrow Transplant 16(1):108–114
Bassim CW, Fassil H, Mays JW, Edwards D, Baird K, Steinberg SM et al (2014) Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures. Bone Marrow Transplant 49(1):116–121
The authors would like to thank the Oral Care Study Group of the Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) for supporting this project.
Conflict of interest
The following authors disclosed their relationship to the BUM-5 study sponsored by Dr. Falk Pharma Ltd.: S. Elad is the medical expert, J.B. Epstein is an investigator, and Y. Zadik is an investigator (no financial relationship with the sponsor). All other co-authors have no conflict of interest to disclose.
The corresponding author has full control of all primary data and agrees to allow the journal to review these data if requested.
Rights and permissions
About this article
Cite this article
Elad, S., Jensen, S.B., Raber-Durlacher, J.E. et al. Clinical approach in the management of oral chronic graft-versus-host disease (cGVHD) in a series of specialized medical centers. Support Care Cancer 23, 1615–1622 (2015). https://doi.org/10.1007/s00520-014-2503-x
- Oral chronic graft-versus-host disease
- NIH scale
- Oral care
- Topical treatment
- Oral mucosa
- Salivary glands
- Oral cancer